- Home
- GRAL vs EYPT Comparison
GRAL vs EYPT Comparison
Compare GRAL & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRAL
- EYPT
- Stock Information
- Founded
- GRAL 2016
- EYPT 1987
- Country
- GRAL United States
- EYPT United States
- Employees
- GRAL N/A
- EYPT N/A
- Industry
- GRAL
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- GRAL
- EYPT Industrials
- Exchange
- GRAL NYSE
- EYPT Nasdaq
- Market Cap
- GRAL 610.9M
- EYPT 594.5M
- IPO Year
- GRAL N/A
- EYPT 2005
- Fundamental
- Price
- GRAL $17.42
- EYPT $7.48
- Analyst Decision
- GRAL Hold
- EYPT Strong Buy
- Analyst Count
- GRAL 2
- EYPT 8
- Target Price
- GRAL $16.00
- EYPT $25.71
- AVG Volume (30 Days)
- GRAL 967.8K
- EYPT 922.9K
- Earning Date
- GRAL 02-15-2025
- EYPT 03-06-2025
- Dividend Yield
- GRAL N/A
- EYPT N/A
- EPS Growth
- GRAL N/A
- EYPT N/A
- EPS
- GRAL N/A
- EYPT N/A
- Revenue
- GRAL $117,669,000.00
- EYPT $45,713,000.00
- Revenue This Year
- GRAL $32.48
- EYPT N/A
- Revenue Next Year
- GRAL $14.72
- EYPT N/A
- P/E Ratio
- GRAL N/A
- EYPT N/A
- Revenue Growth
- GRAL 111.83
- EYPT 7.50
- 52 Week Low
- GRAL $12.33
- EYPT $6.90
- 52 Week High
- GRAL $24.92
- EYPT $30.99
- Technical
- Relative Strength Index (RSI)
- GRAL N/A
- EYPT 44.49
- Support Level
- GRAL N/A
- EYPT $7.15
- Resistance Level
- GRAL N/A
- EYPT $8.25
- Average True Range (ATR)
- GRAL 0.00
- EYPT 0.66
- MACD
- GRAL 0.00
- EYPT -0.01
- Stochastic Oscillator
- GRAL 0.00
- EYPT 22.01
About GRAL GRAIL INC
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.